Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
What is the goal of the study?
These are the main purposes of this study: Test if it is feasible to grow the chimeric antigen receptor-expressing T cells (CD33CART) in the laboratory. Test the safety of giving the CD33CART cells to children and young adults with acute myeloid leukemia. We will watch for side effects. Test how your disease responds when you are given the CD33CART cells after a chemotherapy regimen. Measure how long the CD33CART cells live in your blood and/or bone marrow. We will look for the effects on your immune cells. This trial is in partnership with Fred Hutchinson Cancer Center.
Who can participate in the study?
This study might be a good fit for children and young adults who: Are ages 1 to 34 years old. Have relapsed/refractory acute myeloid leukemia without a central nervous system disease. Have a suitable allogeneic HCT donor and a performance status of more than 50%.